Professor explores generic drug effectiveness

(Medical Xpress)—It's likely if you're sick, your doctor is more inclined to prescribe a brand name drug in place of its generic equivalent. Or maybe you would rather pick up some Advil for that headache, instead of the less expensive pharmacy brand of ibuprofen.

While most patients don't mind paying a premium for brand-name drugs, their generic equivalents could work just as well. The problem is, more research needs to be done in order to determine which generics are on par with brand name drugs, said Dr. Robert Hegele, who teaches Medicine and Biochemistry at Western.

"Doctors and patients tend to think generics work differently. In terms of physicians, there is a feeling that generics are generally OK. But some do believe generics don't seem to work as well," he said.

While this may be true, Hegele said, some generic brands work just as well as their brand-name equivalents and prescribing them could decrease the cost, and increase the provision, of health care.

"With the pressure our health care is under, (prescribing generic brand drugs) is one way to make the best treatments available to the greatest number of patients, because of the reduced cost of drugs," he explained.

Hegele published a paper he co-authored in the April 2013 issue of the , examining the therapeutic benefits of Lipitor – a and one of the most widely prescribed medications in Canada – alongside its generic equivalent.

Titled Clinical Equivalence of Proprietary and Generic in Lipid Clinic Patients, the paper covers a study that looked at a large group of patients who took both Lipitor and generic atorvastatin over a prolonged period of time, ultimately showing no significant changes in the efficacy, or patient management when taking the generic.

"In Ontario, when a physician prescribes atorvastatin in its generic name, the patient might come back three to six months later, and their cholesterol is up. The physician will say, 'It's that darn generic,' but it could be other things. The patient could have changed their diet, gained weight or not have taken the medication as prescribed," Hegele explained.

He and his team looked at a large group of patients who needed to be on Lipitor, switching them to generic atorvastatin and monitoring effects and cholesterol levels.

"After six months, and in some cases a year or more, there was no difference in the efficacy of the drug. To us, it provided reassurance, and comfort to physicians and patients, to switch to a generic," he said.

Looking at the findings objectively, Hegele said generic atorvastatin, on average, works just as well as Lipitor, and their large-scale study is sufficient evidence of that.

"When generic companies do this (type of study), they're only required to do so with a small group of patients, for a short period of time. But there is a large number of patients in the real world who need the medication," he explained.

Still, it's important to note his team only looked at proprietary and generic atorvastatin, Hegele continued.

"We can't comment on generic blood pressure medication, or for diabetes, or the birth control pill. We didn't look at that and in fact, there may be differences. But studies may well find the generic is not as good, or it could be better."

And that's where Hegele thinks improvement is needed in order to provide effective, feasible care to as many as possible and save in the health care industry.

"I really think more studies of this type need to be done. We need real world assessment."

More information: www.onlinecjc.ca/article/S0828-282X%2812%2900271-1/abstract

add to favorites email to friend print save as pdf

Related Stories

First generic version of cancer drug Doxil approved

Feb 04, 2013

(HealthDay)—The first generic version of the cancer drug Doxil (doxorubicin hydrochloride liposome injection) has been approved by the U.S. Food and Drug Administration, which says the action should help relieve shortages ...

High court weighs drug companies' generics policy

Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

Americans turn to generic medications in 2010: report

Apr 22, 2011

(Medical Xpress) -- In a new report released by the IMS Institute for Healthcare Informatics, the results show that over 78% of the almost four billion prescriptions written in the U.S. in 2010 were for generic drugs. The ...

Recommended for you

Study recalculates costs of combination vaccines

11 hours ago

One of the most popular vaccine brands for children may not be the most cost-effective choice. And doctors may be overlooking some cost factors when choosing vaccines, driving the market toward what is actually a more expensive ...

Drug watchdog urges vigilance in cancer drug theft

14 hours ago

Europe's medicine watchdog urged doctors Thursday to be vigilant in administering the cancer drug Herceptin, vials of which had been stolen in Italy and tampered with before being sold back into the supply chain.

Pyridoxine-doxylamine drug safety data lacking

Apr 16, 2014

(Medical Xpress)—The most commonly prescribed drug for pregnant women suffering from morning sickness in their first trimester does not prevent birth defects even though drug safety data says it does, according to research ...

User comments